Moody's Rating for Bone Therapeutics

MOODY'S ANALYTICS RISK SCORE

5

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Bone Therapeutics SA engages in the provision of medical research and development. It focuses on bone cell therapy in the field of orthopaedics and bone diseases. It operates through the following segments: Hips; Fracture Repair; Spinal Implants and Instrumentation; Bone Growth Stimulation; and Orthobiologics. The Hips segment refers to implants such as prosthesis used to replace failed hips. The Fracture Repair segment covers all the materials used today for repairing fresh fractures both internally and externally such as plates, screws, intramedullary nails, pins, wires, staples, and external fixators. The Spinal Implants and Instrumentation segment are implants use to treat degenerative disc disease, herniated discs, scoliosis, vertebral fractures such as pedicle screws, plates, rods, hooks, screws, artificial disc motion preserving devices, discectomy tools, and vertebroplasty or kyphoplasty products. The Bone Growth Stimulation segment refers to equipment that is used for treating fractures and in support of spinal fusion to stimulate bone growth through ultrasound, pulsed electromagnetic fields and extracorporeal shock wave therapy. The Orthobiologics segment are allograft and xenograft bone and tissue; synthetic bone graft substitutes; autologous platelet and plasma systems, cell based products for tissue repair, growth factors and bone proteins, soft tissue repair, replacement a reinforcement products; anti-adhesion technologies, and hyaluronic acid viscosupplements.